Cohorts
Inclusion / exclusion criteria, locked sample sizes, and curation status across studies.
Cohorts defined
7
Patients across cohorts
1,006
Locked
4
In draft / expanding
3
Arm A — escalation responders
Owner AW · updated 2026-04-21
Size
142
Inclusion
- +Confirmed PDA on histology
- +ECOG 0-1
- +Measurable disease per RECIST 1.1
- +Randomized to dose-escalation arm
Exclusion
- −Prior systemic therapy < 12 months
- −Active CNS metastases
- −Concurrent investigational agent
Arm B — standard-of-care
Owner AW · updated 2026-04-21
Size
124
Inclusion
- +Confirmed PDA on histology
- +ECOG 0-1
- +Randomized to standard-of-care arm
Exclusion
- −Prior systemic therapy < 12 months
- −Hepatic insufficiency (Child-Pugh B/C)
ctDNA MRD-positive sub-cohort
Owner ML · updated 2026-04-26
Size
64
Inclusion
- +Stage III CRC s/p curative resection
- +Detectable ctDNA at week 4 post-op
Exclusion
- −Prior CRC malignancy
- −Inadequate surgical margin
ctDNA MRD-negative sub-cohort
Owner ML · updated 2026-04-12
Size
23
Inclusion
- +Stage III CRC s/p curative resection
- +Undetectable ctDNA at week 4 post-op
Exclusion
- −Inadequate surgical margin
Cirrhotic surveillance — high-risk
Owner RP · updated 2026-03-30
Size
219
Inclusion
- +Compensated cirrhosis (any etiology)
- +Prior nodule on US within 24 mo
Exclusion
- −Active HCC at enrollment
Cirrhotic surveillance — average-risk
Owner RP · updated 2026-03-30
Size
393
Inclusion
- +Compensated cirrhosis (any etiology)
- +No nodule history
Exclusion
- −Decompensation event in past 6 mo
Window-of-opportunity neoadjuvant
Owner JY · updated 2026-04-08
Size
41
Inclusion
- +Resectable PDAC by MDT consensus
- +No prior chemo or radiation
Exclusion
- −Borderline resectable disease
- −Pancreatic NET histology